Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T

John Carroll

Editor & Founder

Ten months after the FDA took the shackles off Poseida’s study for a CAR-T directed against castrate-resistant prostate cancer, the executive team is now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Bipartisan 'pill penalty' fix and other bills vie for inclusion in reconciliation package

Can Bill Anderson save Bayer?

Post-Hoc: Pharma CEOs' alternative reality with Trump

How AI can address ongoing challenges in the life sciences industry

Mov­ing past a pa­tient death, Po­sei­da of­fers an ear­ly snap­shot of proof of ef­fi­ca­cy for a next-gen sol­id tu­mor CAR-T

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T